Also known as Tykerb
Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).Source: Wikipedia
Estimated Total Cost: $3110.78 for an average of 28 days supply
Patients are most commonly prescribed lapatinib to treat breast cancer, metastatic cancer, rabies, and blastomycosis.